查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827487

腦生物標記市場（按生物標記類型、適應症、樣本類型、技術和最終用戶分類）—2025-2032 年全球預測

Brain Biomarkers Market by Biomarker Type, Disease Indication, Sample Type, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦生物標記市場將成長至 407.4 億美元，複合年成長率為 18.41%。

主要市場統計數據
基準年2024年 105.4億美元
預計2025年 125億美元
預測年份：2032年 407.4億美元
複合年成長率（%） 18.41%

概述影響腦生物標記開發和應用未來的科學、臨床、監管和商業性基礎的介紹

隨著分子生物學、影像技術和計算分析技術的融合，腦生物標記研究和商業化的模式正在迅速演變，從而催生出更精準的診斷和預後工具。近期的科學突破提高了神經退化性疾病疾病和急性神經系統疾病中候選生物標記的敏感度和特異性，而樣本處理、數位診斷和監管框架的進步則使更精簡的臨床檢驗途徑成為可能。本簡介概述了關鍵促進因素、相關人員的需求和核心科學範式，旨在為研究人員、臨床醫生、投資者和產業領導者提供策略決策參考。

理解這一領域需要綜合觀點，將技術平台與臨床終點和最終用戶的採用動態連結起來。基因圖譜的進步、影像能力的提升以及體液檢測的增強，為在疾病發展早期提供臨床可操作的洞見提供了越來越大的潛力。同時，醫療保健系統面臨壓力，需要優先考慮能夠改善療效、降低醫療成本並支持個人化治療方法的診斷方法。

本節概述了科學、監管和商業性力量如何轉變優先事項，為執行摘要奠定了基礎。它還強調了多學科合作、嚴格的驗證標準和戰略投資對於將有前景的生物標記從發現轉化為常規臨床應用的重要性。闡明這些基本主題有助於讀者更好地理解後續分析，包括不斷變化的市場格局、細分市場的細微差別、區域動態、公司策略以及可行的建議。

深入分析將加速多模態腦生物標記的檢驗和臨床轉化的技術、監管和協作轉變

腦生物標記領域正在經歷數次變革，這些變革正在重新定義研究重點和商業化路徑。首先，精準醫療的需求正推動該領域從單一分析物測量轉向整合基因、蛋白質體學、代謝組學和影像學資訊的多模態特徵。分析靈敏度的提高和縱向資料集的豐富性支持了這種整合趨勢，從而增強了生物標記組和演算法決策支援工具的臨床相關性。

其次，技術的成熟正在加速通量提升並降低檢測成本，使其能夠在科學研究和臨床領域中得到更廣泛的應用。高解析度成像方案和次世代定序儀平台正變得越來越普及，而質譜分析和先進的免疫檢測則提高了基於生物流體的標記物的可重複性。這些能力與數位健康工具相輔相成，這些工具有助於遠端樣本收集和真實世界數據收集，從而增強了跨不同患者群體的證據生成能力。

第三，隨著新診斷方法顯示出明確的臨床效用，監管方法和付款方考量也在不斷演變。健康系統和付款方越來越關注基於價值的證據，這些證據將生物標記的使用與改善患者預後、簡化治療途徑或成本抵消聯繫起來。因此，申辦方正在適應強調積極臨床效用、衛生經濟學和可行性的研究設計。

最後，共同研究模式正在興起，對於加速檢驗和應用至關重要。官民合作關係、資料聯盟和多中心臨床網路正在應對可重複性挑戰，並支援更大規模、更多樣化的檢驗隊列。這些轉變共同創造了一個充滿活力的環境，在這個環境中，創新、證據嚴謹性和實用部署策略必須相互融合，才能充分發揮腦生物標記的潛力。

美國近期關稅調整對 2025 年腦生物標記計畫的採購、供應鏈彈性和商業化計畫的營運和策略影響

政策環境影響了供應鏈、試劑成本、設備採購和跨境合作，而美國近期在2025年之前的關稅變化，也為整個價值鏈上的相關人員帶來了新的營運考量。關稅調整影響了進口儀器零件、專用試劑和實驗室耗材，迫使採購團隊重新評估籌資策略和成本結構。為此，許多機構增加了供應商多元化，協商了長期合約以緩解價格波動，並加快了供應商資格認證流程，以保持關鍵檢測的連續性。

供應鏈重組也延伸至國際夥伴關係，合作研究項目修改了其時間表和物流工作流程，以應對潛在的海關延誤和增加的到岸成本。這些運作調整對研究吞吐量和初步試驗時間表產生了下游影響，尤其對於依賴進口成像硬體、定序試劑和高靈敏度檢測試劑套件的專案而言。因此，研究規劃人員優先考慮關鍵路徑項目，並採用分階段檢驗方法，以保持發展勢頭，同時限制短期成本壓力。

關稅引發的轉變也凸顯了國內製造和本地夥伴關係的戰略價值。探索聯合開發和製造外包協議的相關人員尋求冗餘資源，並降低貿易政策波動帶來的風險。在替代本地供應有限的情況下，各組織投資於穩健的庫存策略和靈活的預算，以在不損害研究完整性的情況下吸收意外的成本成長。

最後，這些貿易政策動態凸顯了靈活商業化策略的必要性。尋求進入或拓展美國市場的公司重新調整了定價模式，完善了價值價值命題定價調整的合理性，並儘早與付款人溝通以強化其報銷方案。總而言之，2025 年的關稅調整促使企業進行務實的營運轉變，並對供應鏈韌性和在地化能力進行了長期投資。

全面的細分整合揭示了生物標記類型、適應症、樣本基質、技術和最終用戶的融合點，從而確定開發和採用途徑的優先順序

細緻的細分框架清楚地闡明了科學機會與商業性吸引力的交會點。就生物標記類型而言，遺傳標記物包括基因表現標記、微型RNA標記和單核苷酸多態性標記物，每種標記物在洞察疾病機制和預測分析潛力方面均具有獨特的優勢。電腦斷層掃描、磁振造影造影和正子斷層掃描等影像技術可提供空間分辨的解剖和功能數據，補充分子層面的數據。同時，在腦脊髓液、血漿和唾​​液中測量的蛋白質生物標記具有不同的靈敏度和易於獲取的臨床應用特徵。

在評估疾病適應症時，阿茲海默症、癲癇、多發性硬化症、帕金森氏症和中風等優先領域呈現不同的檢驗途徑和臨床終點。每種適應症對診斷準確性、縱向監測和治療效果都有獨特的要求，從而影響技術開發和臨床試驗設計。包括血漿和血清在內的血液採集方法可提供微創採樣，適用於更廣泛的篩檢和縱向監測，而腦脊髓液則在接近中樞神經系統病理時具有更高的分析靈敏度。唾液和尿液是方便分散採集的基質，但臨床效用通常需要提高檢測靈敏度。

技術平台的選擇對於分析效能和可擴展性至關重要。層析法技術（例如 HPLC 和 UHPLC）、免疫測量（例如 ELISA 和橫向流動化驗） 、質譜（例如 GC-MS 和 LC-MS）、下一代定序方法（包括標靶定序和全基因組定序）以及 PCR 方法（例如數位 PCR 和 qPCR）在通量、靈敏度和調節成熟度方面各有優劣。最終用戶細分（合約研究組織、診斷實驗室、醫院、製藥公司和研究機構）決定了商業化和服務交付策略，因為這些買家群體的採用時間和採購流程差異很大。整合這些細分可以揭示優先發展的路徑，其中模式、適應症、樣本類型和技術相互協調，以實現可行的臨床和商業性成果。

影響美洲、中東和非洲以及亞太地區臨床檢驗、監管途徑和商業化策略的區域動態

美洲、歐洲、中東和非洲以及亞太地區的區域動態對研究合作、監管預期、報銷環境和基礎設施投資有重大影響。在美洲，強大的臨床研究網路和成熟的支付系統為後期檢驗和支付方參與提供了有利的環境，而私人和公共資金流則支持轉化研究舉措和技術商業化。該地區還擁有大量先進的診斷實驗室和學術醫療中心，能夠進行複雜的多中心研究並產生真實世界證據。

歐洲、中東和非洲 (EMEA) 地區是一個多元化的地區，協調一致的監管環境、集中式的醫療技術評估以及多樣化的醫療保健服務模式正在塑造其應用路徑。該地區的多個市場正在優先考慮早期診斷干預措施和國家篩檢項目，這為已驗證的、在人群層面上顯示出益處的生物標記創造了機會。同時，中東和北非地區的新興市場正在快速發展診斷基礎設施，並建立策略夥伴關係，以獲取先進技術。

亞太地區的特點是生物技術和診斷製造領域投入巨大，臨床試驗能力不斷提升，患者群體迅速擴大。監管改革和加強本地製造的舉措正在加速新型診斷產品的市場化，而數位化醫療的普及和遠端醫療則支持分散式檢查和縱向病患監測。該地區研究機構與產業合作夥伴之間的跨國合作，正在增強對不同患者群體的可及性，並加速跨遺傳和環境背景的生物標記的檢驗。

在每個地區，相關人員必須將證據生成、監管策略和商業化計劃與當地付款人的期望、臨床實踐模式和基礎設施能力相結合。認知到這些差異有助於制定有針對性的上市方案，並更有效地協調全球多中心臨床計畫。

策略競爭分析重點介紹平台整合、夥伴關係和嚴格的臨床檢驗如何區分腦生物標記生態系統中的主要企業

在腦生物標誌生態系統中營運的主要企業透過整合平台策略、策略夥伴關係以及對臨床檢驗的投入來展現其真實世界的價值，從而脫穎而出。成功的公司將深厚的檢測開發專業知識與可擴展的生產流程以及應對複雜核准和報銷流程的監管知識相結合。診斷公司、設備製造商、藥品贊助商和學術中心之間的合作聯盟能夠加速臨床樣本的獲取，擴大檢驗隊列，並為與治療計畫相關的伴隨診斷創建協作開發途徑。

領導力策略也強調跨模式的投資組合多元化，以對沖技術風險並應對更廣泛的疾病適應症。投資模組化、可互通平台（例如，與用例無關的檢測方法、血漿和唾​​液基質，以及協調成像和分子數據的分析流程）的公司可以滿足多種客戶和用例的需求。此外，展示透明分析驗證並發布同儕審查績效數據的公司將增強臨床醫生和付款人的信心，並降低採用門檻。

創新主導的小型企業通常專注於利基檢測和實行技術，例如新型試劑、演算法和樣本儲存解決方案，這使得它們成為大型企業收購或授權的目標。而成熟的診斷和儀器製造商則利用其全球分銷網路和監管經驗，快速擴展經過驗證的解決方案。在競爭格局中，內部研發、外部合作和策略併購之間的平衡將決定企業上市速度和獲得持續商業性吸引力的能力。

為領導者提供切實可行的建議，以協調證據產生、供應鏈彈性和量身定做的商業化策略，從而加速臨床應用

產業領導者應優先產生符合臨床決策點和付款人價值框架的證據，以加速採用和報銷。設計前瞻性實用性試驗，展示生物標記引導的決策如何改善患者預後或最佳化資源利用率，將強化價值提案並減少採用阻力。同時，公司應投資於結合基因、蛋白質、代謝物和影像數據的多模態檢驗策略，以提高診斷準確性並為治療決策提供更豐富的資訊。

在營運方面，企業必須建構具有韌性的供應鏈和靈活的製造結構，以緩解政策和貿易相關的干擾。本地生產能力、合格的二級供應商以及動態庫存模型，可以最大限度地減少外部衝擊的影響，並保持關鍵檢測的連續性。同時，加強數據互通性和標準化報告將使臨床實驗室和衛生系統更容易將新的生物標記物整合到現有的工作流程和電子健康記錄系統中。

商業性來看，相關人員應根據最終用戶的具體需求自訂其上市策略，並認知到醫院、診斷實驗室、研究機構、受託研究機構和製藥公司各自需要不同的證據包、服務模式和打入市場策略方法。儘早與付款方和衛生技術評估機構合作，有助於完善研究終點和證據產生計劃，使其符合報銷標準。最後，領導者應尋求策略合作和聯盟，以接觸不同的患者群體，分擔檢驗成本，並加速就臨床效用標準達成共識。

我們透明的調查方法結合了初步訪談、二次文獻綜述和嚴格的分析框架，以確保可複製和可操作的研究結果。

本報告整合了原始研究和二手資料、專家訪談以及嚴謹的調查方法框架，以確保研究結果的可靠性和透明度。原始研究包括對臨床研究人員、實驗室主任、行業高管和付款方的結構化訪談，旨在就營運挑戰、檢驗重點和應用促進因素提供紮實的見解。二手研究則利用同行評審文獻、監管指南文件和技術白皮書，檢驗診斷應用的技術性能特徵和歷史先例。

分析方法包括對相關人員訪談進行定性主題分析、將技術能力聲明與已發表的分析檢驗研究進行交叉驗證，以及基於情境的政策變化對營運影響的評估。特別關注不同樣本基質和實驗室間檢測表現的可重複性，以及監管機構和付款方期望的證據與臨床終點的一致性。調查方法強調透明度，附錄中記錄了研究納入標準、訪談通訊協定和分析假設，以支持可重複性，並方便讀者評估其在自身項目中的適用性。

在適當的情況下，敏感性分析探討了替代的營運路徑和證據策略，強調風險規避和策略權衡。這種綜合方法確保建議既反映了經驗數據，也反映了實際可行性，相關人員規劃科學項目、臨床檢驗和商業化策略提供了嚴謹的基礎。

總結性結論強調，綜合證據策略、操作敏捷性和跨部門合作對於實現生物標記的影響至關重要

總而言之，腦生物標記領域正處於曲折點，科學進步、技術成熟以及不斷變化的政策環境為改善多種神經系統疾病的診斷、監測和治療發展創造了切實的機會。要實現這一潛力，需要有意識地整合多模態數據、進行能夠證明臨床效用的實用檢驗設計，以及建立一個能夠適應供應鏈和政策波動的彈性運作框架。

開發人員、臨床研究網路、付款方和醫療保健提供者之間的策略合作將加速將有前景的標誌物轉化為常規臨床實踐。投資可互通的平台、進行嚴格的分析檢驗以及早期的付款方參與對於確保採用和報銷至關重要。此外，與當地監管期望和基礎設施能力相符的區域策略將增強全球擴張的前景。

最終，那些兼具科學嚴謹性、營運遠見和合作夥伴關係的組織將引領腦生物標記的下一波創新浪潮。未來的道路是協作和循證主導的，那些優先考慮患者和醫療保健系統價值的利益相關人員將釋放出最大的臨床和商業性影響力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合多體學數據和機器學習，精確分析阿茲海默症的腦生物標記
  • 商業化超靈敏免疫檢測，用於從血漿樣本中早期檢測帕金森氏症病理
  • 使用穿戴式腦電圖和神經影像技術開發用於即時認知監測的數位生物標記平台
  • 全球臨床實驗室致力於標準化腦脊髓液Tau和澱粉樣BETA蛋白的定量
  • 多發性硬化症和神經膠母細胞瘤治療通訊協定中針對標靶治療的伴隨診斷生物標記測試的成長
  • 利用血液中的外泌體微型RNA特徵作為創傷性腦損傷嚴重程度和預後的非侵入性指標
  • 擴大急診室的照護現場生物標記檢測以快速區分卒中亞型
  • 整合人工智慧驅動的影像分析，用於臨床試驗中基於 PET 的神經發炎生物標記定量
  • 標準腦網路連結指數作為預測精神疾病發生和進展的生物標記的出現

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：腦生物標記市場（按生物標記類型）

  • 遺傳
    • 基因表現標記
    • 米爾娜·馬克
    • SNP標記
  • 影像學
    • CT
    • MRI
    • PET
  • 代謝物
    • 脂質代謝物
    • 小分子代謝物
  • 蛋白質
    • 腦脊髓液蛋白
    • 血漿蛋白
    • 唾液蛋白

第9章：腦生物標記市場（依疾病適應症）

  • 阿茲海默症
  • 癲癇
  • 多發性硬化症
  • 帕金森氏症
  • 中風

第 10 章腦生物標記市場（按樣本類型）

  • 血
    • 電漿
    • 血清
  • 腦脊髓液
  • 唾液
  • 尿

第 11 章腦生物標記市場（按技術）

  • 層析法
    • HPLC
    • UHPLC
  • 免疫檢測
    • ELISA
    • 橫向流動化驗
  • 質譜法
    • GC-MS
    • LC-MS
  • 次世代定序
    • 標靶定序
    • 全基因組序列分析
  • PCR
    • 數位PCR
    • QPCR

第 12 章腦生物標記市場（按最終用戶）

  • 受託研究機構
  • 診斷實驗室
  • 醫院
  • 製藥公司
  • 研究所

第 13 章：腦生物標記市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章腦生物標記市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的腦生物標記市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Bio-Rad Laboratories, Inc.
    • Quanterix Corporation
    • Fujirebio Holdings, Inc.
    • PerkinElmer, Inc.
    • Bio-Techne Corporation
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market is projected to grow by USD 40.74 billion at a CAGR of 18.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.54 billion
Estimated Year [2025] USD 12.50 billion
Forecast Year [2032] USD 40.74 billion
CAGR (%) 18.41%

An integrated introduction outlining the scientific, clinical, regulatory, and commercial foundations shaping the future of brain biomarker development and adoption

The landscape of brain biomarker research and commercialization is rapidly advancing as molecular biology, imaging modalities, and computational analytics converge to create more precise diagnostic and prognostic tools. Recent scientific breakthroughs have improved the sensitivity and specificity of candidate biomarkers across neurodegenerative and acute neurological conditions, while parallel progress in sample processing, digital diagnostics, and regulatory frameworks is enabling more streamlined clinical validation pathways. This introduction frames the key drivers, stakeholder needs, and core scientific paradigms that inform strategic decisions for researchers, clinicians, investors, and industry leaders.

Understanding this field requires an integrated perspective that connects technology platforms with clinical endpoints and end-user adoption dynamics. Advances in genetic profiling, expanded imaging capabilities, and enhanced biofluid assays are increasingly capable of delivering clinically actionable insights earlier in disease trajectories. At the same time, healthcare systems are under pressure to prioritize diagnostics that improve outcomes, reduce cost of care, and support personalized therapeutic approaches.

This section sets the stage for the executive summary by outlining how converging scientific, regulatory, and commercial forces are reshaping priorities. It highlights the importance of cross-disciplinary collaboration, robust validation standards, and strategic investments to translate promising biomarkers from discovery into routine clinical use. By establishing these foundational themes, the reader can better interpret subsequent analysis on shifts in the landscape, segmentation nuances, regional dynamics, company strategies, and actionable recommendations.

Detailed analysis of converging technological, regulatory, and collaborative shifts that are accelerating multimodal brain biomarker validation and clinical adoption

The brain biomarker landscape is experiencing several transformative shifts that are redefining research priorities and commercialization pathways. First, precision medicine imperatives are moving the field beyond single-analyte readouts toward multimodal signatures that combine genetic, proteomic, metabolite, and imaging-derived information. This integrative trend is supported by improved analytic sensitivity and richer longitudinal datasets, which together elevate the clinical relevance of biomarker panels and algorithmic decision-support tools.

Second, technology maturation is accelerating throughput and reducing assay costs, thereby enabling broader deployment in both research and clinical settings. High-resolution imaging protocols and next generation sequencing platforms have become more accessible, while mass spectrometry and advanced immunoassays are delivering higher reproducibility for biofluid-based markers. These capabilities are complemented by digital health tools that facilitate remote sample collection and real-world data capture, strengthening evidence generation across diverse patient cohorts.

Third, regulatory approaches and payer considerations are shifting to accommodate novel diagnostics that demonstrate clear clinical utility. Health systems and payers are increasingly focused on value-based evidence linking biomarker use to improved patient outcomes, pathway efficiencies, or cost offsets. Consequently, sponsors are adapting study designs to emphasize prospective clinical utility, health economics, and implementation feasibility.

Finally, collaborative models are emerging as essential to accelerate validation and adoption. Public-private partnerships, data consortia, and multi-center clinical networks are addressing reproducibility challenges and enabling larger, more diverse validation cohorts. Taken together, these shifts create a dynamic environment in which innovation, evidence rigor, and practical deployment strategies must align to realize the full potential of brain biomarkers.

Operational and strategic ramifications of recent United States tariff adjustments in 2025 shaping procurement, supply chain resilience, and commercialization planning for brain biomarker initiatives

The policy environment influences supply chains, reagent costs, instrument procurement, and cross-border collaborations, and recent tariff changes in the United States for 2025 introduced new operational considerations for stakeholders across the value chain. Tariff adjustments affected imported instrumentation components, specialized reagents, and laboratory consumables, prompting procurement teams to reassess sourcing strategies and cost structures. In response, many organizations intensified supplier diversification, negotiated long-term contracts to mitigate price volatility, and accelerated vendor qualification processes to maintain continuity of critical assays.

Supply chain recalibration extended to international partnerships, where collaborative research programs reassessed timelines and logistical workflows to account for potential customs delays and higher landed costs. These operational adjustments had a downstream effect on research throughput and pilot study timelines, particularly for programs reliant on imported imaging hardware, sequencing reagents, and high-sensitivity assay kits. Consequently, study planners prioritized critical-path items and adopted phased validation approaches to preserve momentum while containing near-term cost pressures.

Tariff-induced shifts also highlighted the strategic value of domestic manufacturing and local partnerships. Stakeholders exploring co-development and contract manufacturing agreements sought to build redundancy and reduce exposure to trade policy fluctuations. Where local supply alternatives were limited, organizations invested in robust inventory strategies and instituted adaptive budgeting to absorb episodic cost increases without compromising study integrity.

Finally, these trade policy dynamics underscored the need for flexible commercialization strategies. Companies seeking to enter or expand in the U.S. market recalibrated pricing models, refined value propositions to justify list pricing changes, and engaged payers earlier to reinforce reimbursement narratives. In sum, the 2025 tariff adjustments catalyzed pragmatic operational shifts and encouraged longer-term investments in supply chain resilience and localized capabilities.

Comprehensive segmentation synthesis revealing where biomarker type, indication, sample matrix, technology, and end user converge to prioritize development and adoption pathways

A nuanced segmentation framework brings clarity to where scientific opportunity and commercial traction intersect. Considering biomarker type, genetic markers encompass gene expression markers, microRNA markers, and single nucleotide polymorphism markers, each offering distinct advantages in terms of disease mechanism insight and potential for predictive analytics. Imaging modalities including computed tomography, magnetic resonance imaging, and positron emission tomography deliver spatially resolved anatomical and functional data that complement molecular readouts. Metabolite assays span lipid metabolites and small molecule metabolites, which can reflect dynamic biochemical states and metabolic dysregulation, while protein-based biomarkers measured in cerebrospinal fluid, plasma, and saliva offer varied sensitivity and accessibility profiles for clinical use.

When evaluating disease indications, priority areas such as Alzheimer's disease, epilepsy, multiple sclerosis, Parkinson's disease, and stroke illustrate diverse validation pathways and clinical endpoints. Each indication presents unique requirements for diagnostic accuracy, longitudinal monitoring, and therapeutic impact, shaping both technical development and clinical study design. Sample type segmentation further refines feasibility and adoption considerations: blood-based approaches, including plasma and serum, offer minimally invasive sampling suitable for broader screening and longitudinal monitoring, while cerebrospinal fluid provides proximity to central nervous system pathology and greater analytical sensitivity. Saliva and urine represent convenient matrices for decentralized collection but often require enhanced assay sensitivity to reach clinical utility.

Technology platform selection matters for analytical performance and scalability. Chromatography techniques such as HPLC and UHPLC, immunoassays including ELISA and lateral flow assays, mass spectrometry variants like GC-MS and LC-MS, next generation sequencing approaches encompassing targeted and whole genome sequencing, and PCR modalities including digital PCR and qPCR each present trade-offs in throughput, sensitivity, and regulatory maturity. End-user segmentation comprising contract research organizations, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes shapes commercialization and service delivery strategies, as adoption timelines and procurement processes differ substantially across these buyer groups. Integrating these layers of segmentation reveals prioritized development pathways where modality, indication, sample type, and technology align to achieve feasible clinical and commercial outcomes.

Regional dynamics shaping clinical validation, regulatory pathways, and commercialization strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence research collaborations, regulatory expectations, reimbursement environments, and infrastructure investments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust clinical research networks and established payer systems provide a conducive environment for late-stage validation and payer engagement, while significant private and public funding streams support translational initiatives and technology commercialization. This region also exhibits substantial concentration of advanced diagnostic laboratories and academic medical centers that can execute complex multi-center studies and real-world evidence generation.

Europe, the Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts, centralized health technology assessment frameworks, and diverse healthcare delivery models shape adoption pathways. Several markets within this region prioritize early diagnostic interventions and national screening programs, creating opportunities for validated biomarkers that demonstrate population-level benefit. Meanwhile, emerging markets across the Middle East & Africa are rapidly building diagnostic infrastructure and forming strategic partnerships to access advanced technologies.

Asia-Pacific is characterized by substantial investment in biotech and diagnostic manufacturing, fast-growing clinical trial capacity, and a rapidly expanding patient population. Regulatory reforms and initiatives to strengthen local manufacturing are accelerating market entry for novel diagnostics, while digital health adoption and telemedicine expansion support decentralized testing and longitudinal patient monitoring. Cross-border collaborations between research institutes and industry partners in the region are enhancing access to diverse patient cohorts and facilitating accelerated validation of biomarkers across different genetic and environmental backgrounds.

Across all regions, stakeholders must tailor evidence generation, regulatory strategy, and commercialization plans to local payer expectations, clinical practice patterns, and infrastructure capabilities. Recognizing these distinctions enables targeted market entry approaches and more effective global coordination of multi-site clinical programs.

Strategic competitive analysis highlighting how platform integration, partnerships, and rigorous clinical validation differentiate leading players in the brain biomarker ecosystem

Key companies operating in the brain biomarker ecosystem are differentiating through integrated platform strategies, strategic partnerships, and investment in clinical validation to demonstrate real-world value. Successful organizations combine deep domain expertise in assay development with scalable manufacturing processes and regulatory know-how to navigate complex approval and reimbursement landscapes. Collaborative alliances between diagnostics firms, instrument manufacturers, pharmaceutical sponsors, and academic centers accelerate access to clinical samples, expand validation cohorts, and create co-development pathways for companion diagnostics linked to therapeutic programs.

Leadership strategies also emphasize portfolio diversification across modalities to hedge technical risk and address a broader set of disease indications. Companies that invest in modular, interoperable platforms - for example, assays that can be adapted across CSF, plasma, or saliva matrices, or analytical pipelines that harmonize imaging and molecular data - position themselves to serve multiple customers and use cases. In addition, firms that demonstrate transparent analytical validation and publish peer-reviewed performance data foster greater clinician and payer trust, smoothing adoption hurdles.

Smaller, innovation-driven companies often focus on niche assays or enabling technologies such as novel reagents, algorithms, or sample preservation solutions, creating acquisition or licensing targets for larger players. Meanwhile, established diagnostic and instrument companies leverage global distribution networks and regulatory experience to scale validated solutions rapidly. Across the competitive landscape, the balance between internal R&D, external partnerships, and strategic M&A determines speed to market and ability to achieve sustainable commercial traction.

Actionable recommendations for leaders to align evidence generation, supply chain resilience, and tailored commercialization strategies that accelerate clinical adoption

Industry leaders should prioritize evidence generation that aligns with clinical decision points and payer value frameworks to accelerate adoption and reimbursement. Designing prospective utility studies that demonstrate how biomarker-informed decisions improve patient outcomes or optimize resource use will strengthen value propositions and reduce adoption friction. Simultaneously, organizations should invest in multimodal validation strategies that combine genetic, protein, metabolite, and imaging data to enhance diagnostic precision and provide richer context for therapeutic decision-making.

Operationally, companies must build resilient supply chains and flexible manufacturing arrangements to mitigate policy and trade-related disruptions. Localized production capabilities, qualified secondary suppliers, and dynamic inventory models will minimize the impact of external shocks and preserve continuity for critical assays. In parallel, strengthening data interoperability and standardized reporting will make it easier for clinical laboratories and health systems to integrate new biomarkers into existing workflows and electronic health record systems.

Commercially, stakeholders should tailor go-to-market strategies to specific end-user needs, recognizing that hospitals, diagnostic labs, research institutes, contract research organizations, and pharmaceutical companies require different evidence packages, service models, and pricing approaches. Early engagement with payers and health technology assessment bodies can refine study endpoints and evidence generation plans to align with reimbursement criteria. Finally, leaders should pursue strategic collaborations and consortium participation to access diverse patient cohorts, share validation costs, and accelerate consensus on clinical utility standards.

Transparent research methodology combining primary interviews, secondary literature review, and rigorous analytic frameworks to ensure reproducible and actionable insights

This report synthesizes primary and secondary research, expert interviews, and rigorous methodological frameworks to ensure robust and transparent findings. Primary research included structured interviews with clinical investigators, laboratory directors, industry executives, and payers, providing grounded insights into operational challenges, validation priorities, and adoption drivers. Secondary research drew upon peer-reviewed literature, regulatory guidance documents, and technology white papers to triangulate technical performance characteristics and historical precedent for diagnostic adoption.

Analytical methods included qualitative thematic analysis of stakeholder interviews, cross-validation of technology capability claims against published analytical validation studies, and scenario-based assessment of operational impacts arising from policy changes. Special attention was paid to the reproducibility of assay performance across sample matrices and sites, and to the alignment of clinical endpoints with regulatory and payer evidence expectations. The methodology emphasized transparency: criteria for study inclusion, interview protocols, and analytic assumptions are documented in appendices to support reproducibility and allow readers to assess applicability to their own programs.

Where appropriate, sensitivity analyses explored alternative operational pathways and evidence strategies to highlight risk mitigations and strategic trade-offs. The combined approach ensures that recommendations reflect both empirical data and practical feasibility, providing stakeholders with a rigorous foundation for planning scientific programs, clinical validation, and commercialization tactics.

Concluding synthesis emphasizing the imperative for integrated evidence strategies, operational agility, and cross-sector collaboration to realize biomarker impact

In conclusion, the brain biomarker field stands at an inflection point where scientific advances, technological maturity, and evolving policy environments create tangible opportunities to improve diagnosis, monitoring, and therapeutic development across multiple neurological conditions. Realizing this potential requires deliberate integration of multimodal data, pragmatic validation designs that demonstrate clinical utility, and resilient operational frameworks that accommodate supply chain and policy variability.

Strategic alignment among developers, clinical research networks, payers, and healthcare providers will accelerate translation from promising markers to routine clinical practice. Investments in interoperable platforms, rigorous analytical validation, and early payer engagement will be essential to secure adoption and reimbursement. Additionally, regional strategies tailored to local regulatory expectations and infrastructure capacities will enhance global deployment prospects.

Ultimately, organizations that combine scientific rigor with operational foresight and collaborative partnerships will lead the next wave of innovation in brain biomarkers. The path forward is collaborative and evidence-driven, and stakeholders that prioritize value for patients and health systems will unlock the greatest clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiomics data with machine learning for precision brain biomarker profiling in Alzheimer's disease
  • 5.2. Commercialization of ultra-sensitive immunoassays enabling early detection of Parkinson's disease pathology from plasma samples
  • 5.3. Development of digital biomarker platforms using wearable EEG and neuroimaging for real-time cognitive monitoring
  • 5.4. Standardization initiatives for cerebrospinal fluid tau and amyloid beta quantification across global clinical laboratories
  • 5.5. Growth of companion diagnostic biomarker tests for targeted therapies in multiple sclerosis and glioblastoma treatment protocols
  • 5.6. Utilization of exosomal microRNA signatures in blood as non-invasive indicators of traumatic brain injury severity and prognosis
  • 5.7. Expansion of point-of-care biomarker testing devices for rapid stroke subtype differentiation in emergency care settings
  • 5.8. Integration of AI-driven image analysis to quantify PET-based neuroinflammation biomarkers in clinical trials
  • 5.9. Emergence of normative brain network connectivity metrics as predictive biomarkers for psychiatric disorder onset and progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Biomarkers Market, by Biomarker Type

  • 8.1. Genetic
    • 8.1.1. Gene Expression Markers
    • 8.1.2. Mirna Markers
    • 8.1.3. Snp Markers
  • 8.2. Imaging
    • 8.2.1. Ct
    • 8.2.2. Mri
    • 8.2.3. Pet
  • 8.3. Metabolite
    • 8.3.1. Lipid Metabolites
    • 8.3.2. Small Molecule Metabolites
  • 8.4. Protein
    • 8.4.1. Csf Proteins
    • 8.4.2. Plasma Proteins
    • 8.4.3. Saliva Proteins

9. Brain Biomarkers Market, by Disease Indication

  • 9.1. Alzheimer's Disease
  • 9.2. Epilepsy
  • 9.3. Multiple Sclerosis
  • 9.4. Parkinson's Disease
  • 9.5. Stroke

10. Brain Biomarkers Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
  • 10.2. Cerebrospinal Fluid
  • 10.3. Saliva
  • 10.4. Urine

11. Brain Biomarkers Market, by Technology

  • 11.1. Chromatography
    • 11.1.1. Hplc
    • 11.1.2. Uhplc
  • 11.2. Immunoassay
    • 11.2.1. Elisa
    • 11.2.2. Lateral Flow Assay
  • 11.3. Mass Spectrometry
    • 11.3.1. Gc-ms
    • 11.3.2. Lc-ms
  • 11.4. Next Generation Sequencing
    • 11.4.1. Targeted Sequencing
    • 11.4.2. Whole Genome Sequencing
  • 11.5. Pcr
    • 11.5.1. Digital Pcr
    • 11.5.2. Qpcr

12. Brain Biomarkers Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Brain Biomarkers Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Danaher Corporation
    • 16.3.5. Abbott Laboratories
    • 16.3.6. Bio-Rad Laboratories, Inc.
    • 16.3.7. Quanterix Corporation
    • 16.3.8. Fujirebio Holdings, Inc.
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Bio-Techne Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HPLC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY UHPLC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LC-MS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 333. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 334. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 335. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 336. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MI